218 related articles for article (PubMed ID: 20586799)
1. Health economics in haemophilia: a review from the clinician's perspective.
Escobar MA
Haemophilia; 2010 May; 16 Suppl 3():29-34. PubMed ID: 20586799
[TBL] [Abstract][Full Text] [Related]
2. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
[TBL] [Abstract][Full Text] [Related]
3. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
4. Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.
Hay JW; Chaugule SC; Young G
Haemophilia; 2013 Sep; 19(5):711-9. PubMed ID: 23672765
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
6. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
Knight C; Danø AM; Kennedy-Martin T
Haemophilia; 2009 Mar; 15(2):405-19. PubMed ID: 19187191
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
[TBL] [Abstract][Full Text] [Related]
9. Cost of care of haemophilia with inhibitors.
Di Minno MN; Di Minno G; Di Capua M; Cerbone AM; Coppola A
Haemophilia; 2010 Jan; 16(1):e190-201. PubMed ID: 19845772
[TBL] [Abstract][Full Text] [Related]
10. aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model.
Kim CH; Simmons SC; Bui CM; Jiang N; Pham HP
Vox Sang; 2019 Jan; 114(1):63-72. PubMed ID: 30499154
[TBL] [Abstract][Full Text] [Related]
11. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
Szmurło D; Deryło Ł; Ryś P; Władysiuk M
Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
[TBL] [Abstract][Full Text] [Related]
12. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
[TBL] [Abstract][Full Text] [Related]
13. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
Hay JW; Zhou ZY
Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802
[TBL] [Abstract][Full Text] [Related]
14. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
Villarrubia R; Oyagüez I; Álvarez-Román MT; Mingot-Castellano ME; Parra R; Casado MA
Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.
Salaj P; Kubes R; Cetkovsky P; Capova I; Penka M; Ovesná P; Mesterton J; Lindgren P
Thromb Res; 2014 Feb; 133(2):162-7. PubMed ID: 24321420
[TBL] [Abstract][Full Text] [Related]
16. Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa.
Hay JW; Zhou ZY
J Med Econ; 2011; 14(4):516-25. PubMed ID: 21699366
[TBL] [Abstract][Full Text] [Related]
17. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil.
Ozelo MC; Villaça PR; De Almeida JO; Bueno TM; De Miranda PA; Hart WM; Karamalis M
Haemophilia; 2007 Sep; 13(5):462-9. PubMed ID: 17880430
[TBL] [Abstract][Full Text] [Related]
18. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.
Stephens JM; Joshi AV; Sumner M; Botteman MF
Expert Opin Pharmacother; 2007 Jun; 8(8):1127-36. PubMed ID: 17516876
[TBL] [Abstract][Full Text] [Related]
19. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
Steen Carlsson K; Astermark J; Donfield S; Berntorp E
Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of an adjunctive recombinant activated factor VIIa for on-demand treatment of bleeding episodes in dengue haemorrhagic fever.
Naing C; Poovorawan Y; Mak JW; Aung K; Kamolratankul P
Blood Coagul Fibrinolysis; 2015 Jun; 26(4):403-7. PubMed ID: 25692521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
